Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

RecruitingPhase 1/2

NCT06501625

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta…

The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/cis…

United States52 participantsStarted 2024-12-16

Treatment: Ivosidenib, Durvalumab (for the first 8, 21-day, cycles)

Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta…

All recent trials (1 shown)

Trial phase breakdown

Trial status

Actively recruiting — 1 trial

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Meta…

All recent trials (1 shown)